As groups representing physicians who regularly prescribe biologics, we have a unique and important perspective about the use of these medicines. While biosimilars hold tremendous promise to increase access and affordability of these advanced medicines, their availability will increase the complexity of the treatment landscape. As such, the Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.
The Biologics Prescribers Collaborative’s mission is to ensure that physicians who prescribe complex biologic treatments are given a voice in discussions shaping policies that govern the use of biosimilars. Learn more about our four guiding principles and how we plan to achieve a unified prescriber voice.
April 27, 2017
The Biologics Prescribers Collaborative provides a white paper on "The State of Biosimilars Policy" to educate policy makers as they take actions to encourage the development of these medicines while protecting patient safety and the prescribers’ need for transparent medical data. BPC hopes to ensure that policies governing the approval and use of biosimilars are crafted carefully to include the latest science, reflect clinical best practice, and uphold patient safety. As prescribers of biologics, our unique and important perspective about their use is presented in this white paper, and we will continue to provide Congress and the Administration education to create the needed rigorous policy framework that will promote access to and safe use of biosimilars for the millions of patients in America who could benefit from these medicines. Read More ›
April 11, 2017
The Biologics Prescribers Collaborative is pleased to publish the 2nd edition of our educational handbook, which serves as an introductory primer to key biologic and biosimilar issues. The biosimilars age has arrived with the promise of an expanding array of therapeutic options for patients and physicians battling serious diseases and conditions. As prescribers of biologics, we believe that realizing the biosimilar promise requires awareness of the differences between biosimilars and generics, and among biologics themselves, as well as an understanding of the distinctive therapeutic choices they represent. This introductory handbook provides an overview of the key issues. Read More ›
February 13, 2017
BPC applauds the FDA for issuing final guidance calling for distinguishable names for all biologic medicines. However, as the BPC has voiced to FDA, we remain concerned with “random” suffixes called for in the guidance. As physicians who routinely prescribe biologic medicines, we believe a memorable suffix is needed. One that reflects the manufacturer of the medicine is immediately recognizable and would facilitate prompt, accurate adverse event reporting by patients and physicians to the correct manufacturer and that manufacturer's mandated reporting to FDA. Read More ›
October 3, 2016
Morning Consult published an opinion editorial by Dr. Joshua Stolow of AfPA and CSRO discussing how the FDA has made great strides in developing guidelines for biosimilars, however, there still remain areas that must be addressed to ensure maximum patient safety and efficacy. Read More ›
Stay updated! For more information about the Biologics Prescribers Collaborative, please fill out the following information.